StoneX Group’s ProQR Therapeutics PRQR Stock Holding History

StoneX Group’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,900	Closed	-$31.7K	–	440
2023 Q1	$31.7K	Buy	+14,900	New	+$45.6K	0.02%	334

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

StoneX Group's PRQR Position: Q2 2023 in Review

StoneX Group sold out of ProQR Therapeutics (PRQR) in Q2 2023, closing a stake of 14,900 shares — an estimated $31.7K sold.

StoneX Group first reported a position in PRQR in Q1 2023 and held it in 1 quarter. The position peaked at $31.7K in Q1 2023. 51 funds tracked by Wall St. Rank hold PRQR as of Q2 2023.

StoneX Group reported no remaining ProQR Therapeutics position as of Q2 2023 after selling out during the quarter.
StoneX Group sold 14,900 ProQR Therapeutics shares in Q2 2023, an estimated $31.7K.
StoneX Group first reported a position in ProQR Therapeutics in Q1 2023 and held it in 1 quarter.
StoneX Group's ProQR Therapeutics position peaked at $31.7K in Q1 2023.
51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2023.

Based on StoneX Group's 13F filing for Q2 2023, filed 14 Aug 2023.